Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Repurchased Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Growth Metrics

CV Sciences (CVSI) Gains from Sales and Divestitures (2017 - 2019)

CV Sciences' Gains from Sales and Divestitures history spans 2 years, with the latest figure at $2.9 million for Q4 2019.

On a quarterly basis, Gains from Sales and Divestitures changed N/A to $2.9 million in Q4 2019 year-over-year; TTM through Dec 2019 was $2.9 million, a N/A change, with the full-year FY2019 number at $2.9 million, changed N/A from a year prior.
Gains from Sales and Divestitures hit $2.9 million in Q4 2019 for CV Sciences, up from $2.0 million in the prior quarter.
Over the last five years, Gains from Sales and Divestitures for CVSI hit a ceiling of $2.9 million in Q4 2019 and a floor of $1.0 million in Q1 2017.